Phibro Animal Health (PAHC)
Sells medicated feed additives, vaccines, nutritional specialties, and trace minerals for animal production.
Something off on this page? Send us feedback.
Makes animal-health products, mineral nutrition, and specialty performance ingredients for livestock, aquaculture, dogs, and industrial customers. Animal Health anchors the portfolio through medicated feed additives, nutritional specialties, and vaccines, while sales mix depends on product registrations, food-animal drug rules, and livestock-production cycles.
Develops, manufactures, and markets animal-health products for poultry, swine, beef and dairy cattle, aquaculture, and dogs. Animal Health covers medicated feed additives and related products, nutritional specialties such as OmniGen and Animate, and vaccines including autogenous and aquaculture lines.
Manufactures trace-mineral formulations through Mineral Nutrition, mainly for North American livestock customers, and specialty ingredients through Performance Products for personal care, industrial chemical, and catalyst uses. The United States is the largest sales destination, while Animal Health sells more than half of its segment revenue outside the United States.
Competes through registrations, technical support, product breadth, quality, manufacturing know-how, locations, and price. Many medicated products depend on country-specific approvals and food-animal drug rules, and the recently acquired Zoetis medicated-feed-additive portfolio now sits inside Animal Health.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 6, 2026 | Morgan Stanley | Target | Target: $34 | Target: $49 |
| Jul 7, 2025 | JP Morgan | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $82.0M · Total debt $788.8M · Total assets $1.50B · Shareholders' equity $385.5M
- Revenue
- $396.7M
- Operating income
- $48.2M
- Net income
- $21.7M
HistoryDividendAnnual yield
| Institutions | ≈ 53.15% | 21.58M shares | |
|---|---|---|---|
| 215 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.62% | 250.8K shares | |
| 10 holders · as of Sep 17, 2026 | |||
| Other | ≈ 46.23% | 18.77M shares | |
| remainder | |||
40.60M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.93% | 3.22M A | as of Jun 30, 2026 |
FMR LLCInstitution | 7.78% | 3.16M A | as of Jun 30, 2026 |
State Street CorpInstitution | 2.56% | 1.04M A | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 2.31% | 936,701 A | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.27% | 923,318 A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 29, 2026 | E. Thomas Corcoran | director | +10,000 | $31.77 |
| May 7, 2026 | Jack Bendheim | director, 10 percent owner, officer: President and CEO | −4,528 | $48.49 |
| May 6, 2026 | Jack Bendheim | director, 10 percent owner, officer: President and CEO | −7,040 | $57.37 |
| May 5, 2026 | Jack Bendheim | director, 10 percent owner, officer: President and CEO | −7,040 | $55.80 |
| Apr 30, 2026 | Jack Bendheim | director, 10 percent owner, officer: President and CEO | −7,040 | $52.76 |
- Elanco Animal Health
Farm-animal medicines and production-health products
- Merck
Scaled livestock vaccines and veterinary pharmaceuticals
- Zoetis
Global animal-health leader across livestock medicines and vaccines
- Balchem
Animal nutrition supplier in choline and chelated minerals
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Phibro Animal Health | $34.98 | +0.88% | $1.41B | 14.2 | 10.0 | 0.9 | +4.8% |
| Elanco Animal Health | $22.79 | +1.60% | $11.20B | — | 19.2 | 2.2 | +10.2% |
| Merck | $151.34 | +1.23% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Zoetis | $71.61 | +0.39% | $29.90B | 11.8 | 11.5 | 3.1 | +0.3% |
| Balchem | $169.39 | +1.23% | $5.38B | 32.9 | 30.5 | 5.0 | +11.2% |
| Median | 32.9 | 18.4 | 4.0 | +7.7% |